SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

You should not take Reclast if you're on Zometa® (zoledronic acid) Injection because it contains the same active ingredient. Additionally, you should not take Reclast if you are pregnant, plan to ...

Novartis Pharmaceuticals Corp. in East Hanover, an affiliate of Novartis AG, says it has received approval from the Food and Drug Administration for zoledronic acid (Reclast) injection as a ...

BRAMPTON, Ontario--(BUSINESS WIRE)--Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL ...

Please provide your email address to receive an email when new articles are posted on . “Discontinuation of denosumab results in high-turnover bone loss and increased fracture risk,” Sabashini ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

Randomized phase II study of epirubicin (E) plus cyclophosphamide (C) vs. weekly paclitaxel (P) as primary systemic therapy (PST) in patients (pts) with stage II and III breast cancer (BC) ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.